<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id>
      <journal-title-group>
        <journal-title>BMC Cancer</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2407</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24148527</article-id>
      <article-id pub-id-type="pmc">4015643</article-id>
      <article-id pub-id-type="publisher-id">1471-2407-13-491</article-id>
      <article-id pub-id-type="doi">10.1186/1471-2407-13-491</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>FELD better not thinking of metastases only when liver lesions appear after bleomycin-based treatment for non-seminoma testis from metastases</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" id="A1">
          <name>
            <surname>De Vos</surname>
            <given-names>Filip YFL</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>f.devos@umcutrecht.nl</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Mulder</surname>
            <given-names>Sasja F</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>s.mulder@onco.umcn.nl</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Drenth</surname>
            <given-names>Joost PH</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>j.drenth@mdl.umcn.nl</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Nagtegaal</surname>
            <given-names>Iris D</given-names>
          </name>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>i.nagtegaal@pathol.umcn.nl</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>F&#xFC;tterer</surname>
            <given-names>Jurgen J</given-names>
          </name>
          <xref ref-type="aff" rid="I4">4</xref>
          <email>j.futterer@rad.umcn.nl</email>
        </contrib>
        <contrib contrib-type="author" id="A6">
          <name>
            <surname>van der Graaf</surname>
            <given-names>Winette TA</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>w.vandergraaf@onco.umcn.nl</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Medical Oncology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, Netherlands</aff>
      <aff id="I2"><label>2</label>Department of Gastroenterology and Hepatology, Radboud University, Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, Netherlands</aff>
      <aff id="I3"><label>3</label>Department of Pathology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, Netherlands</aff>
      <aff id="I4"><label>4</label>Department of Radiology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, Netherlands</aff>
      <pub-date pub-type="collection">
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>22</day>
        <month>10</month>
        <year>2013</year>
      </pub-date>
      <volume>13</volume>
      <fpage>491</fpage>
      <lpage>491</lpage>
      <history>
        <date date-type="received">
          <day>30</day>
          <month>11</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>20</day>
          <month>9</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2013 De Vos et al.; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2013</copyright-year>
        <copyright-holder>De Vos et al.; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (
<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.biomedcentral.com/1471-2407/13/491"/>
      <abstract>
        <sec>
          <title>Background</title>
          <p>Bleomycin has become an integral part of chemotherapy in patients with germ-cell tumors. One of the most feared side effects is bleomycin-induced pneumonitis. In patients with mild or moderate BIP, radiological signs disappear almost completely within nine months after discontinuation of bleomycin treatment.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>We present a patient with a history of non seminoma of the testis and bleomycin-induced pneumonitis. During follow-up, regression of the hypothesis of eosinophilic migration to the liver after regression of bleomycin-induced pneumonitis is highly suspicious based on transient eosinophilia and focal eosinophilic liver disease.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>As follow up may consist of CT scanning in germ-line tumor patients, transient eosinophilic liver lesions reported during regressive bleomycin-induced pneumonitis should not be presumed automatically as metastatic tumor relapse and require further sequential imaging and pathological examination.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>Transient</kwd>
        <kwd>Eosinophilia</kwd>
        <kwd>Liver lesions</kwd>
        <kwd>Non-seminoma testis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Bleomycin is a glycopeptide antibiotic produced by the bacterium <italic>Streptomyces verticillus</italic>. Bleomycin acts as an oncolytic agent by inducing DNA strand breakage and subsequent has become an integral part of chemotherapy in patients with germ-cell tumors
[<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Bleomycin-induced toxicity usually targets organs with low hydrolase concentrations i.e. lungs and skin
[<xref ref-type="bibr" rid="B3">3</xref>]. One of the most feared side effects is bleomycin-induced pneumonitis (BIP)
[<xref ref-type="bibr" rid="B4">4</xref>]. BIP is a potential life-threatening interstitial pulmonary fibrosis. Depending on the diagnosis criteria used, up to 46% of patients treated with bleomycin develop BIP
[<xref ref-type="bibr" rid="B4">4</xref>]. Treatment of BIP consists of discontinuation of bleomycin. In severe BIP cases, steroids are indicated, while a case-report mentions imatinib mesylate as a salvage therapy in steroid-resistant BIP
[<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. In patients with mild or moderate BIP, radiological signs disappear almost completely within nine months after discontinuation of bleomycin treatment
[<xref ref-type="bibr" rid="B6">6</xref>]. In this case-report, transient eosinophilia and focal eosinophilic liver lesions occurred simultaneously with regression of BIP lesions, fuelling the hypothesis of eosinophilic migration. It implicates sequential computer tomography (CT) scanning and robust pathologic evidence for diagnosing relapse of testicular cancer in such cases.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>A 41-year-old man was diagnosed with stage IIA good risk non seminoma of the left-sided testis and treated with hemiorchidectomy and adjuvant three cycles of bleomycin, etoposide and cisplatin. He received a total dose of 270 mg bleomycin during treatment. After the last course of chemotherapy, a chest and abdominal CT-scan (CT 1) revealed complete remission of the metastatic lesions. However, we unexpectedly discovered fibrosis in both lungs with signs of bronchiolitis obliterans and focally organizing pneumonia, probably induced by bleomycin (Figure&#xA0;
<xref ref-type="fig" rid="F1">1</xref>a), while liver lesions were absent (Figure&#xA0;
<xref ref-type="fig" rid="F1">1</xref>b). He had no pulmonary complaints. No broncho-alveolar lavage was performed. Our patient was closely monitored according to national guidelines
[<xref ref-type="bibr" rid="B7">7</xref>]. A year after end of chemotherapy, with pulmonary infiltrations resolving (Figure&#xA0;
<xref ref-type="fig" rid="F2">2</xref>a) routine CT scan (CT 4) showed four new hypo-dense lesions in the liver with a maximal diameter of 20 mm (Figure&#xA0;
<xref ref-type="fig" rid="F2">2</xref>b. At that moment, the patient reported no complaints. Tumor markers, human chorionic gonadotropin, alpha fetoprotein levels and lactate dehydrogenase, were normal. Laboratory findings reported 7.3&#xD7;109/l leucocytes with 11% eosinophils (absolute eosinophil count 0.8 &#xD7; 109/l, normal value &lt; 0.5) normal liver enzymes, bilirubin level and liver function tests (prothrombin time, albumin and glucose). The patient had no history of travel related diseases, dietary habits and other risk factors for eosinophilia. Sarcoidosis was ruled out by a normal serum angiotensin-converting enzyme. Hepatitis serology and bacteriological cultures were all negative. Additional, magnetic resonance imaging (MRI) was performed for further characterization (Figure&#xA0;
<xref ref-type="fig" rid="F3">3</xref>a and
<xref ref-type="fig" rid="F3">3</xref>b). On the non-contrast T1-weighted axial MRI image (Figure&#xA0;
<xref ref-type="fig" rid="F3">3</xref>a) a lesion with a hypointense rim and isointense centre was seen. On the contrast enhanced T1-weighted fat-suppressed axial MR image (hepatocyte phase, Figure&#xA0;
<xref ref-type="fig" rid="F3">3</xref>b) a lesion with centrally low signal intensity and rim enhancement suggestive for small abscess was seen. A needle biopsy of one of the liver lesions showed no signs of tumor, normal architecture of central veins and portal fields and portal inflammation with infiltration of eosinophils and lymphocytes with focal necrosis (Figure&#xA0;
<xref ref-type="fig" rid="F4">4</xref>). Extensive discussions in our tumor panel and with our hepatology experts led to the diagnosis of bleomycin induced focal hepatitis with eosinophilic infiltration based on exclusion of other possible diagnoses, time-relationship with BIP regression and pathologic findings. A wait-and-see policy was adopted with CT scanning (CT 6) three months later (Figure&#xA0;
<xref ref-type="fig" rid="F5">5</xref>).</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p><bold>Radiologic findings at the end of chemotherapy. (a)</bold> Fibrosis in both lungs with signs of bronchiolitis obliterans and focally organizing pneumonia; <bold>(b)</bold> No signs of liver lesions.</p>
        </caption>
        <graphic xlink:href="1471-2407-13-491-1"/>
      </fig>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p><bold>Radiologic findings one year after end of chemotherapy. (a)</bold> Pulmonary infiltrations resolving; <bold>(b)</bold> Four new hypo-dense lesions in the liver.</p>
        </caption>
        <graphic xlink:href="1471-2407-13-491-2"/>
      </fig>
      <fig id="F3" position="float">
        <label>Figure 3</label>
        <caption>
          <p><bold>Characterization by MRI. (a)</bold> Lesion with hypointense rim and isointense centre; <bold>(b)</bold> Lesion with centrally low signal intensity and rim enhancement.</p>
        </caption>
        <graphic xlink:href="1471-2407-13-491-3"/>
      </fig>
      <fig id="F4" position="float">
        <label>Figure 4</label>
        <caption>
          <p>Pathologic findings of one of the liver lesions revealing portal inflammation, infiltration of eosinophils and lymphocytes with focal necrosis.</p>
        </caption>
        <graphic xlink:href="1471-2407-13-491-4"/>
      </fig>
      <fig id="F5" position="float">
        <label>Figure 5</label>
        <caption>
          <p>Abdominal CT-scan fifteen months after end of chemotherapy with further regression of pulmonary fibrosis, and regression of liver lesions.</p>
        </caption>
        <graphic xlink:href="1471-2407-13-491-5"/>
      </fig>
      <p>This CT revealed further regression of pulmonary fibrosis, and regression of liver lesions in segment 2 (n&#x2009;=&#x2009;1) and in segment 8 (n&#x2009;=&#x2009;3). At 10 months one lesion was further decreased 3 lesions were stable. Interestingly, subsequent blood measurements showed a normalization of the percentage eosinophils in the three months between the first occurrence of liver lesions on CT and second CT with diminishment of these liver lesions and eventually calcification. This leads to the hypothesis that both findings are related to each other (Figure&#xA0;
<xref ref-type="fig" rid="F6">6</xref>).</p>
      <fig id="F6" position="float">
        <label>Figure 6</label>
        <caption>
          <p><bold>Excel-file graph of absolute eosinophil count over time.</bold> Absolute eosinophil count, with a normal value of &lt; 0,5 &#xD7; 109/l OK= operation orchidectomy BEP&#x2009;= chemotherapy course with Bleomycine, Etoposide and Cisplatin CT1 = CT scan with bilateral pulmonary infiltrations, no liver abnormalities (Figure
<xref ref-type="fig" rid="F1">1</xref>) CT2 = CT scan with decreased pulmonary fibrosis, no liver abnormalities CT3 = CT scan with decreased pulmonary fibrosis, no liver abnormalities CT4 = CT scan with remains of pulmonary fibrosis and 4 liver lesions (Figure
<xref ref-type="fig" rid="F2">2</xref>) MRI = MRI liver, 4 liver lesions (Figure
<xref ref-type="fig" rid="F3">3</xref>a and
<xref ref-type="fig" rid="F3">3</xref>b) CT5 = CT scan with remains of pulmonary fibrosis and 4 decreased liver lesions CT6 = CT scan with remains of pulmonary fibrosis and 3 liver lesions stable, 1 decreased (Figure
<xref ref-type="fig" rid="F5">5</xref>) CT7 = CT scan with remains of pulmonary fibrosis and 4 liver lesions stable with central calcifications.</p>
        </caption>
        <graphic xlink:href="1471-2407-13-491-6"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>We have seen the concomittant regression of BIP and onset of focal eosinophilic liver disease (FELD) with eosinophilia. By exclusion diagnosis and thorough pathologic examination, this relationship in time led to the hypothesis of eosinophilic migration. Our understanding of the pathogenesis of BIP is mainly based on data derived from animal studies. Endothelial damage of the lung vasculature by bleomycin-induced free radicals is associated with an acquired loss of bleomycin hydrolase activity and followed by an influx of inflammatory cells
[<xref ref-type="bibr" rid="B8">8</xref>]. There is a significant correlation between eosinophilia and bleomycin-induced pulmonary fibrosis
[<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. Apart from T-lymphocytes, eosinophils are key players in the production of tumor growth factor-&#x3B2;, platelet-derived growth factor receptor-&#x3B1; and tumor necrosis factor-&#x3B1;, leading to proliferation and accumulation of fibroblasts. On their turn, fibroblasts produce chemotactic cytokines recruiting eosinophils
[<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. The trigger for the self-limiting nature of BIP remains elusive due to complex interaction between several T-lymphocyte related chemokines
[<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. We hypothesize that pulmonary eosinophils and fibroblasts migrate to other organs such as the liver, leading to transient eosinophila and focal eosinophilic accumulation. FELD is a well-known disease entity that is associated with a variety of pathological conditions including parasitic infestations, allergy, internal malignancies, drug hypersensitivity, and hypereosinophilic syndrome
[<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. FELD can be differentiated from hepatic metastases using CT or MRI scanning. A significant smaller lesion size on unenhanced T1-weighted compared to hepatocyte phase imaging (delayed phased) and an ill-defined margin and isointensity on T1 weighted images can distinguish FELD from liver hepatic metastases
[<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B19">19</xref>]. These characteristics were also observed in our patient. The biopsy-proven eosinophilic infiltrations had irregular, fuzzy margins, while arterial hyperintensity was lacking. In our patient, liver biopsy revealed typical FELD characteristics. Nevertheless, after extensive biochemical, serological and bacteriological testing, no specific cause, related to a transient appearance of eosinophilia and eosinophil infiltration in the liver, was determined. Yet, a clear time-relationship was observed between eosinophilia and the onset of pulmonary fibrosis and liver lesions and normalization of eosinophil count and regression of pulmonary fibrosis and liver lesions (Figure&#xA0;
<xref ref-type="fig" rid="F6">6</xref>). This lead to the hypothesis of interrelated cause and effect. Focal liver lesions in patients with BIP do not necessarily imply the relapse of germcell tumors as is demonstrated in our case. It is always a challenge to differentiate between metastatic or nonmetastatic liver lesions (Table&#xA0;
<xref ref-type="table" rid="T1">1</xref>). It is likely that corticosteroids given for BIP, for example in case of severe pulmonary symptoms, would ameliorate the intense inflammatory reaction
[<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. However, as corticosteroids have not direct effect on the initial inflammatory reaction leading to BIP, our patient would not have benefited and the liver lesions would probably still have emerged.</p>
      <table-wrap position="float" id="T1">
        <label>Table 1</label>
        <caption>
          <p>Differential diagnosis between metastatic liver lesions and FELD</p>
        </caption>
        <table frame="hsides" rules="groups" border="1">
          <colgroup>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
          </colgroup>
          <thead valign="top">
            <tr>
              <th align="left">&#xA0;</th>
              <th align="left">
                <bold>Metastatic liver lesion</bold>
              </th>
              <th align="left">
                <bold>FELD</bold>
              </th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" valign="bottom">Incidence/100,000<hr/></td>
              <td align="left" valign="bottom">8 &#x2013; 20<hr/></td>
              <td align="left" valign="bottom">3 &#x2013; 4<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Solitary<hr/></td>
              <td align="left" valign="bottom">5 &#x2013; 10%<hr/></td>
              <td align="left" valign="bottom">90%<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Pathogenesis<hr/></td>
              <td align="left" valign="bottom">Hematogenous or lymphatic spread of cancer<hr/></td>
              <td align="left" valign="bottom">parasitic infestations, allergy, internal malignancies, drug hypersensitivity, and hypereosinophilic syndrome<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Imaging<hr/></td>
              <td align="left" valign="bottom">US, CT<hr/></td>
              <td align="left" valign="bottom">Two-phase dynamic CT, MRI<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Alpha fetoprotein; human chorionic gonadotropin<hr/></td>
              <td align="left" valign="bottom">Elevated (in case of non-seminoma testis)<hr/></td>
              <td align="left" valign="bottom">Normal<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Calcification<hr/></td>
              <td align="left" valign="bottom">Possible<hr/></td>
              <td align="left" valign="bottom">None<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Characteristic gross features<hr/></td>
              <td align="left" valign="bottom">Hemorrhage, necrosis with rim enhancement on CT, spherical shape<hr/></td>
              <td align="left" valign="bottom">indistinct margins, absence of rim enhancement, nonspherical shape<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Characteristic microscopic features<hr/></td>
              <td align="left" valign="bottom">Replacement of hepatocytes, by malignant cells no portal structures<hr/></td>
              <td align="left" valign="bottom">focal eosinophilic accumulation<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Diagnosis<hr/></td>
              <td align="left" valign="bottom">FNAB or core biopsy<hr/></td>
              <td align="left" valign="bottom">FNAB or core biopsy<hr/></td>
            </tr>
            <tr>
              <td align="left">Treatment</td>
              <td align="left">Resection, RFA or chemotherapy</td>
              <td align="left">Depending underlying disease</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p><italic>US</italic>: ultrasound; <italic>CT</italic>: computerized tomography; <italic>MRI</italic>: magnetic resonance imaging; <italic>FNAB</italic>: fine needle aspiration biopsy for cytology; <italic>RFA</italic>: radiation frequency ablation.</p>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusion</title>
      <p>In this patient the hypothesis of eosinophilic migration to the liver after regression of BIP is suggestive given the transient eosinophilia and presence of FELD. As follow up may consist of CT scanning in germ-line tumor patients, transient eosinophilic liver lesions reported during regressive BIP should not be presumed automatically as metastatic tumor relapse and require further sequential imaging and pathological examination.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Patient has given his consent for publication of case-report.</p>
    </sec>
    <sec>
      <title>Abbreviations</title>
      <p>BIP: Bleomycin-induced pneumonitis; CT: Computer tomography; FELD: Focal eosinophilic liver disease; MRI: Magnetic resonance imaging.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>No funding sources need to be credited. No conflicts of interest should bementioned.</p>
    </sec>
    <sec>
      <title>Authors&#x2019; contributions</title>
      <p>IN provided the figures of pathological findings. JF provided the figures of radiological findings. All authors read and approved the final manuscript.</p>
    </sec>
    <sec>
      <title>Pre-publication history</title>
      <p>The pre-publication history for this paper can be accessed here:</p>
      <p>
        <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/13/491/prepub">http://www.biomedcentral.com/1471-2407/13/491/prepub</ext-link>
      </p>
    </sec>
  </body>
  <back>
    <sec>
      <title>Acknowledgements</title>
      <p>No grant support needs to be reported. Data from the manuscript were not presented at previous meetings. No disclaimers have to be made.</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>de Wit</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Stoter</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Sleijfer</surname>
            <given-names>DT</given-names>
          </name>
          <name>
            <surname>Kaye</surname>
            <given-names>SB</given-names>
          </name>
          <name>
            <surname>de Mulder</surname>
            <given-names>PH</given-names>
          </name>
          <name>
            <surname>ten Bokkel Huinink</surname>
            <given-names>WW</given-names>
          </name>
          <name>
            <surname>Spaander</surname>
            <given-names>PJ</given-names>
          </name>
          <name>
            <surname>de Pauw</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Sylvester</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Four cycles of BEP versus an alternating regimen of PVB and BEP in patients with poorprognosis metastatic testicular non-seminoma; a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group</article-title>
          <source>Br J - Cancer</source>
          <year>1995</year>
          <volume>13</volume>
          <fpage>1311</fpage>
          <lpage>1314</lpage>
          <comment>1195</comment>
          <pub-id pub-id-type="doi">10.1038/bjc.1995.254</pub-id>
          <pub-id pub-id-type="pmid">7540039</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>de Wit</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Stoter</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Sleijfer</surname>
            <given-names>DT</given-names>
          </name>
          <name>
            <surname>Neijt</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>Ten Bokkel Huinink WW</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Prijck</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Collette</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Sylvester</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Four cycles of BEP vs. four cycles of VIP in patients with intermediate-prognosis metastatic testicular nonseminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group</article-title>
          <source>Br J Cancer</source>
          <year>1998</year>
          <volume>13</volume>
          <fpage>828</fpage>
          <lpage>832</lpage>
          <pub-id pub-id-type="doi">10.1038/bjc.1998.587</pub-id>
          <pub-id pub-id-type="pmid">9743309</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Sikic</surname>
            <given-names>BI</given-names>
          </name>
          <article-title>Biochemical and cellular determinants of bleomycin cytotoxicity</article-title>
          <source>Cancer Surv</source>
          <year>1986</year>
          <volume>13</volume>
          <fpage>81</fpage>
          <lpage>91</lpage>
          <pub-id pub-id-type="pmid">2439200</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Sleijfer</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Bleomycin-induced pneumonitis</article-title>
          <source>Chest</source>
          <year>2001</year>
          <volume>13</volume>
          <fpage>617</fpage>
          <lpage>624</lpage>
          <pub-id pub-id-type="doi">10.1378/chest.120.2.617</pub-id>
          <pub-id pub-id-type="pmid">11502668</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Carnevale-Schianca</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Gallo</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Rota-Scalabrini</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Sangiolo</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Fizzotti</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Caravelli</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Capaldi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Anselmetti</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Palesandro</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>D&#x2019;Ambrosio</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Coha</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Obert</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Aglietta</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Grignani</surname>
            <given-names>G</given-names>
          </name>
          <article-title>Complete resolution of lifethreatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin&#x2019;s lymphoma: hope for severe chemotherapy-induced toxicity?</article-title>
          <source>J Clin Oncol</source>
          <year>2011</year>
          <volume>13</volume>
          <fpage>691</fpage>
          <lpage>693</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2011.35.6733</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Bellamy</surname>
            <given-names>EA</given-names>
          </name>
          <name>
            <surname>Husband</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Blaquiere</surname>
            <given-names>RM</given-names>
          </name>
          <name>
            <surname>Law</surname>
            <given-names>MR</given-names>
          </name>
          <article-title>Bleomycin-related lung damage: CT evidence</article-title>
          <source>Radiology</source>
          <year>1985</year>
          <volume>13</volume>
          <fpage>155</fpage>
          <lpage>158</lpage>
          <pub-id pub-id-type="pmid">2408293</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="other">
          <name>
            <surname>de Wit</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Gietema</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>de Reijke</surname>
            <given-names>TM</given-names>
          </name>
          <name>
            <surname>Battermann</surname>
            <given-names>JJ</given-names>
          </name>
          <name>
            <surname>van den Bergh</surname>
            <given-names>ACM</given-names>
          </name>
          <name>
            <surname>van Gils</surname>
            <given-names>FCJM</given-names>
          </name>
          <name>
            <surname>de Kaa CA</surname>
            <given-names>H-v</given-names>
          </name>
          <name>
            <surname>de Jong</surname>
            <given-names>IJ</given-names>
          </name>
          <name>
            <surname>Los</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>van Moorselaar</surname>
            <given-names>RJA</given-names>
          </name>
          <name>
            <surname>Witjes</surname>
            <given-names>JA</given-names>
          </name>
          <article-title>Testicarcinoom: landelijke richtlijn</article-title>
          <comment>
            <ext-link ext-link-type="uri" xlink:href="http://www.oncoline.nl/testiscarcinoom">http://www.oncoline.nl/testiscarcinoom</ext-link>
          </comment>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Filderman</surname>
            <given-names>AE</given-names>
          </name>
          <name>
            <surname>Genovese</surname>
            <given-names>LA</given-names>
          </name>
          <name>
            <surname>Lazo</surname>
            <given-names>JS</given-names>
          </name>
          <article-title>Alterations in pulmonary protective enzymes following systemic bleomycin treatment in mice</article-title>
          <source>Biochem Pharmacol</source>
          <year>1988</year>
          <volume>13</volume>
          <fpage>1111</fpage>
          <lpage>1116</lpage>
          <pub-id pub-id-type="doi">10.1016/0006-2952(88)90518-7</pub-id>
          <pub-id pub-id-type="pmid">2451525</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Huaux</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>McGarry</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Ullenbruch</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Xing</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Phan</surname>
            <given-names>SH</given-names>
          </name>
          <article-title>Eosinophils and T-lymphocytes possess distinct roles in bleomycininduced lung injury and fibrosis</article-title>
          <source>J Immunol</source>
          <year>2003</year>
          <volume>13</volume>
          <fpage>5470</fpage>
          <lpage>5481</lpage>
          <pub-id pub-id-type="pmid">14607953</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Cui</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Kusunose</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Hamada</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Ono</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Miyamura</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Yoshioka</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kyotani</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Nishioka</surname>
            <given-names>Y</given-names>
          </name>
          <article-title>Relationship between the eosinophilia of bronchoalveolar lavage fluid (BALF) and the severity of pulmonary fibrosis induced by bleomycin in rats</article-title>
          <source>Biol Pharm Bull</source>
          <year>2003</year>
          <volume>13</volume>
          <fpage>959</fpage>
          <lpage>963</lpage>
          <pub-id pub-id-type="doi">10.1248/bpb.26.959</pub-id>
          <pub-id pub-id-type="pmid">12843618</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Sato</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Koyama</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Robbins</surname>
            <given-names>RA</given-names>
          </name>
          <article-title>Bleomycin stimulates lung fibroblast and epithelial cell lines to release eosinophil chemotactic activity</article-title>
          <source>Eur Respir J</source>
          <year>2000</year>
          <volume>13</volume>
          <fpage>951</fpage>
          <lpage>958</lpage>
          <pub-id pub-id-type="pmid">11153598</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Phillips</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Burdick</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Hong</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Lutz</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Murray</surname>
            <given-names>LA</given-names>
          </name>
          <name>
            <surname>Xue</surname>
            <given-names>YY</given-names>
          </name>
          <name>
            <surname>Belperio</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Keane</surname>
            <given-names>MP</given-names>
          </name>
          <name>
            <surname>Strieter</surname>
            <given-names>RM</given-names>
          </name>
          <article-title>Circulating fibrocytes traffic to the lungs in response to CXCL 12 and mediate fibrosis</article-title>
          <source>J Clin Invest</source>
          <year>2004</year>
          <volume>13</volume>
          <fpage>438</fpage>
          <lpage>446</lpage>
          <pub-id pub-id-type="pmid">15286810</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Mehrad</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Burdick</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Strieter</surname>
            <given-names>RM</given-names>
          </name>
          <article-title>Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis</article-title>
          <source>Int J Biochem Cell Biol</source>
          <year>2009</year>
          <volume>13</volume>
          <fpage>1708</fpage>
          <lpage>1718</lpage>
          <pub-id pub-id-type="doi">10.1016/j.biocel.2009.02.020</pub-id>
          <pub-id pub-id-type="pmid">19433312</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Pochetuhen</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Luzina</surname>
            <given-names>IG</given-names>
          </name>
          <name>
            <surname>Lockatell</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Choi</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Todd</surname>
            <given-names>NW</given-names>
          </name>
          <name>
            <surname>Atamas</surname>
            <given-names>SP</given-names>
          </name>
          <article-title>Complex regulation of pulmonary inflammation and fibrosis by CCL18</article-title>
          <source>Am J Pathol</source>
          <year>2007</year>
          <volume>13</volume>
          <fpage>428</fpage>
          <lpage>437</lpage>
          <pub-id pub-id-type="doi">10.2353/ajpath.2007.061167</pub-id>
          <pub-id pub-id-type="pmid">17569779</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kim</surname>
            <given-names>GB</given-names>
          </name>
          <name>
            <surname>Kwon</surname>
            <given-names>JH</given-names>
          </name>
          <name>
            <surname>Kang</surname>
            <given-names>DS</given-names>
          </name>
          <article-title>Hypereosinophilic syndrome: imaging findings in patients with hepatic involvement</article-title>
          <source>Am J Roentgenol</source>
          <year>1993</year>
          <volume>13</volume>
          <fpage>577</fpage>
          <lpage>580</lpage>
          <pub-id pub-id-type="doi">10.2214/ajr.161.3.8352109</pub-id>
          <pub-id pub-id-type="pmid">8352109</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Lee</surname>
            <given-names>WJ</given-names>
          </name>
          <name>
            <surname>Lim</surname>
            <given-names>HK</given-names>
          </name>
          <name>
            <surname>Lim</surname>
            <given-names>JH</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>SH</given-names>
          </name>
          <name>
            <surname>Choi</surname>
            <given-names>SH</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>SJ</given-names>
          </name>
          <article-title>Foci of eosinophilrelated necrosis in the liver: imaging findings and correlation with eosinophilia</article-title>
          <source>Am J Roentgenol</source>
          <year>1999</year>
          <volume>13</volume>
          <fpage>1255</fpage>
          <lpage>1261</lpage>
          <pub-id pub-id-type="doi">10.2214/ajr.172.5.10227499</pub-id>
          <pub-id pub-id-type="pmid">10227499</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Hur</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Park</surname>
            <given-names>MS</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Lim</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Hong</surname>
            <given-names>SW</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>KW</given-names>
          </name>
          <article-title>Focal eosinophilic necrosis versus metastasis in the liver: the usefulness of two-phase dynamic CT</article-title>
          <source>Am J Roentgenol</source>
          <year>2005</year>
          <volume>13</volume>
          <fpage>1085</fpage>
          <lpage>1090</lpage>
          <pub-id pub-id-type="doi">10.2214/ajr.184.4.01841085</pub-id>
          <pub-id pub-id-type="pmid">15788577</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kim</surname>
            <given-names>YK</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>YH</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>CS</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>MW</given-names>
          </name>
          <article-title>Differentiating focal eosinophilic liver disease from hepatic metastases using enhanced and gadoxetic acid-enhanced MRI</article-title>
          <source>Abdom Imaging</source>
          <year>2011</year>
          <volume>13</volume>
          <fpage>425</fpage>
          <lpage>432</lpage>
          <pub-id pub-id-type="doi">10.1007/s00261-011-9752-7</pub-id>
          <pub-id pub-id-type="pmid">21748468</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Suzuki</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Brunt</surname>
            <given-names>EM</given-names>
          </name>
          <name>
            <surname>Kleiner</surname>
            <given-names>DE</given-names>
          </name>
          <name>
            <surname>Miquel</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Smyrk</surname>
            <given-names>TC</given-names>
          </name>
          <name>
            <surname>Andrade</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Lucena</surname>
            <given-names>MI</given-names>
          </name>
          <name>
            <surname>Castiella</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Lindor</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Bj&#xF6;rnsson</surname>
            <given-names>E</given-names>
          </name>
          <article-title>The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury</article-title>
          <source>Hepatology</source>
          <year>2011</year>
          <volume>13</volume>
          <fpage>931</fpage>
          <lpage>939</lpage>
          <pub-id pub-id-type="doi">10.1002/hep.24481</pub-id>
          <pub-id pub-id-type="pmid">21674554</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation publication-type="journal">
          <name>
            <surname>White</surname>
            <given-names>DA</given-names>
          </name>
          <name>
            <surname>Stover</surname>
            <given-names>DE</given-names>
          </name>
          <article-title>Severe bleomycin-induced pneumonitis Clinical features and response to corticosteroids</article-title>
          <source>Chest</source>
          <year>1984</year>
          <volume>13</volume>
          <fpage>723</fpage>
          <lpage>728</lpage>
          <pub-id pub-id-type="doi">10.1378/chest.86.5.723</pub-id>
          <pub-id pub-id-type="pmid">6207992</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
